Overview

Topical Imiquimod in Treating Patients With Recurrent Paget's Disease of the Vulva

Status:
Completed
Trial end date:
2018-01-01
Target enrollment:
0
Participant gender:
Female
Summary
RATIONALE: Biological therapies, such as imiquimod, may stimulate the immune system in different ways and stop tumor cells from growing. Applying topical imiquimod to the vulva may be an effective treatment for recurrent Paget's disease. PURPOSE: This clinical trial is studying how well topical imiquimod works in treating patients with recurrent Paget's disease of the vulva.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborators:
National Cancer Institute (NCI)
Ohio State University
Treatments:
Imiquimod
Criteria
Inclusion Criteria:

All patients presenting to the Gynecology outpatient service at a participating institution
who meet eligibility requirements may be included in this clinical trial. The eligibility
requirements are as follows:

- Age ≥18.

- Ability to give informed consent.

- Patients must have biopsy proven recurrent extramammary Paget's disease confirmed at
the participating site.

Exclusion Criteria:

- Patients with known hypersensitivity to imiquimod.

- Pregnant and nursing women are not eligible

- Patients with underlying adenocarcinoma on biopsy of lesion confirmed at the
participating site.